Alterity Therapeutics Limited
ATHE
$4.82
-$0.08-1.63%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | 73.75% | 51.65% | 32.42% | 20.90% | 7.90% |
| Total Revenue | 73.75% | 51.65% | 32.42% | 20.90% | 7.90% |
| Cost of Revenue | -11.74% | -28.11% | -41.25% | -29.85% | -19.28% |
| Gross Profit | 78.11% | 55.94% | 36.57% | 24.07% | 9.80% |
| SG&A Expenses | 19.23% | 16.00% | 14.04% | 26.37% | 39.52% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 278.07% | 375.83% | 1,567.65% | 1,028.57% | 666.00% |
| Total Operating Expenses | -2.27% | -9.67% | -16.26% | 10.10% | 47.73% |
| Operating Income | 16.07% | 21.50% | 26.23% | -7.62% | -58.32% |
| Income Before Tax | 28.00% | 33.02% | 37.32% | -1.05% | -59.65% |
| Income Tax Expenses | 174.34% | 107.89% | 41.78% | 137.01% | 7,500.00% |
| Earnings from Continuing Operations | 27.53% | 32.68% | 37.13% | -1.26% | -60.01% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 27.53% | 32.68% | 37.13% | -1.26% | -60.01% |
| EBIT | 16.07% | 21.50% | 26.23% | -7.62% | -58.32% |
| EBITDA | 15.99% | 21.47% | 26.24% | -7.67% | -58.52% |
| EPS Basic | 60.32% | 61.37% | 61.74% | 41.36% | 20.38% |
| Normalized Basic EPS | 53.49% | 55.45% | 56.45% | 38.78% | 20.68% |
| EPS Diluted | 60.83% | 61.07% | 60.75% | 40.52% | 19.83% |
| Normalized Diluted EPS | 53.49% | 55.45% | 56.45% | 38.78% | 20.68% |
| Average Basic Shares Outstanding | 74.72% | 74.97% | 75.31% | 87.04% | 104.33% |
| Average Diluted Shares Outstanding | 74.72% | 74.97% | 75.31% | 87.04% | 104.33% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |